What's breaking now, across thousands of outlets.
Phase 3 trial underway for iopofosine I 131 in Waldenstrom's macroglobulinemia.
We haven't written up this one. Motley Fool has the full story — the link below goes straight to it.
This is one outlet's version. Read the fullest account.
Defense demand fuels record consumables revenue amid MarkForged acquisition push.
MUMBAI: Indian lenders’ retail foreign exchange pricing shows a gap between regulatory intent and market outcome and banks should put in place clear policies governing charges and timelines, central…
The world’s largest employer expects to pass on tariff refunds for lower consumer prices.
Defense backlog surged 100% as the company scales domestic refractory metals production.
DefenCath revenue hit $66.1M as CorMedix expands dialysis partnerships and advances REZZAYO.
DropSite News exposes how the too-cutely-named Israel front Honest Reporting managed to secure funds from the Knight Foundation
